Phase 2 Results in the Treatment of Macular Edema Associated with Retinal Vein Occlusion
Phase 2 and Phase 1/2 Results in the Treatment of Macular Edema Associated with Non-Infectious Uveitis
ALPHARETTA, Ga., Oct. 10, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that results from two clinical trials, including the TANZANITE trial, “Safety and Efficacy of Suprachoroidal Triamcinolone Acetonide Concomitant with Intravitreal Aflibercept: Phase 2 Retinal Vein Occlusion (RVO) Study”, will be presented at the Retina Sub-Specialty Day Meeting at the 2016 American Academy of Ophthalmology (AAO) Meeting, October 14-15, 2016, in Chicago, IL.
David M. Brown, MD, a prominent Houston, TX-based retinal specialist and thought leader on the research and treatment of RVO, age-related macular degeneration (AMD) and diabetic macular edema (DME) will present the results of the three-month TANZANITE clinical trial conducted in patients with macular edema associated with RVO:
- Suprachoroidal Triamcinolone Acetonide Concomitant with IVT Aflibercept: Phase 2 Retinal Vein Occlusion (RVO) Study. [October 15, 3:18 p.m. – 3:23 p.m.]
Diana V. Do, MD, Professor of Ophthalmology, Vice Chair for Education Director of the Carl Camras Center for Innovative Clinical Trials in Ophthalmology, Director of the Ophthalmology Residency Training Program and the Director of Retina Fellowship Training Program at the University of Nebraska College of Medicine will present clinical results from both the DOGWOOD Phase 2 trial and the Phase 1/2 trial conducted in patients with macular edema associated with non-infectious uveitis:
- Innovative Suprachoroidal Microneedle. [October 15, 12:18 p.m. – 12:24 p.m.]
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly-traded, late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary suprachoroidal space microinjector to reach diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye. Clearside has a portfolio of clinical and pre-clinical programs using drug administration through the suprachoroidal space to provide a route of access to treat diseases of the back-of-the-eye such as RVO, uveitis, wet AMD and DME. Clearside is currently enrolling patients in a Phase 3 clinical trial (PEACHTREE) for the treatment of patients with macular edema associated with non-infectious uveitis and has initiated IND-enabling studies for the treatment of wet AMD. Visit www.clearsidebio.com for more information.
Contacts Company: Charles Deignan Chief Financial Officer 678-270-4005 charlie.deignan@clearsidebio.com Investors: Matthew Beck The Trout Group 646-378-2933 mbeck@troutgroup.com
